<!DOCTYPE html> 
<html lang="ru"> 
<head> 
	<meta charset="UTF-8"> 
	<meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no"> 
	<link rel="shortcut icon" href="images/favicon.ico"> 
	<link rel="stylesheet" href="style.css"> 
	<title></title> 
</head> 
<body class="">
<svg id="mask-1" width="0" height="0" viewBox="0 0 824 724"><clipPath id="hexagonClipPath" clipPathUnits="objectBoundingBox" transform="scale(0.0012, 0.00138)"><path d="M226.525 0.672501C212.235 0.672501 199.03 8.29646 191.884 20.6725L6.30594 342.104C-0.839373 354.48 -0.839369 369.728 6.30594 382.104L191.884 703.535C199.03 715.911 212.235 723.535 226.525 723.535L597.682 723.535C611.973 723.535 625.178 715.911 632.323 703.535L817.902 382.104C825.047 369.728 825.047 354.48 817.902 342.104L632.323 20.6725C625.178 8.29645 611.973 0.672501 597.682 0.672501L226.525 0.672501Z" fill="none"/></clipPath></svg>
<svg id="mask-2" width="0" height="0" viewBox="0 0 263 301"><clipPath id="hexClipPath" clipPathUnits="objectBoundingBox" transform="scale(0.0038, 0.00332)"><path d="M115.97 4.78856C125.33 -0.74153 136.862 -0.74153 146.223 4.78855L246.97 64.3096C256.33 69.8397 262.096 80.0597 262.096 91.1199V210.162C262.096 221.222 256.33 231.442 246.97 236.972L146.223 296.493C136.862 302.024 125.33 302.024 115.97 296.493L15.2228 236.972C5.86241 231.442 0.0961914 221.222 0.0961914 210.162V91.1199C0.0961914 80.0597 5.86241 69.8397 15.2228 64.3096L115.97 4.78856Z" fill="none"/></clipPath></svg> <header class="header " data-scroll-lock-fill-gap>
	<div class="header__inner">
		<a href="./" class="header__logo"><img src="./images/logo.png" alt=""></a>
		<navi class="header__navi">
			<a class="header__navi-link" href="./page.html">Company</a>
			<a class="header__navi-link" href="./page2.html">Capabilities</a>
			<a class="header__navi-link" href="./page3.html">Careers at CBM</a>
			<a class="header__navi-link" href="./contacts.html">Contact Us</a>
			<a class="header__navi-link" href="./">News</a>
		</navi>

		<div class="header__menu-blind" data-scroll-lock-scrollable>
			<ul class="header__menu menu">
				<li class="menu__item menu__item_haschild">
					<a class="menu__link" href="./page.html">Company</a>
					<ul class="menu__submenu">
						<li class="menu__item"><a class="menu__link" href="./page2.html">CBM: Mission, Vision & Values</a></li>
						<li class="menu__item"><a class="menu__link" href="./page3.html">CBM Difference</a></li>
						<li class="menu__item"><a class="menu__link" href="./page4.html">CMB Teams</a></li>
					</ul>
				</li>
				<li class="menu__item menu__item_haschild">
					<a class="menu__link" href="./page5.html">Capabilities</a>
					<ul class="menu__submenu">
						<li class="menu__item"><a class="menu__link" href="./page6.html">Process Development</a></li>
						<li class="menu__item"><a class="menu__link" href="./page7.html">Testing & Analytical</a></li>
						<li class="menu__item"><a class="menu__link" href="./page8.html">Viral Vector Manufacturing</a></li>
						<li class="menu__item"><a class="menu__link" href="./page9.html">Cell Therapy Manufacturing</a></li>
						<li class="menu__item"><a class="menu__link" href="./page10.html">Plasmid DNA</a></li>
						<li class="menu__item"><a class="menu__link" href="./page11.html">Cell Banking</a></li>
					</ul>
				</li>
				<li class="menu__item"><a href="./" class="menu__link">Careers at CBM</a></li>
				<li class="menu__item"><a href="./contacts.html" class="menu__link">Contact Us</a></li>
			</ul>
		</div>

		<div class="header__menu-toggle">
			<button>
				<span>Close</span>
				<span>Discover more</span>
			</button>
		</div>
	</div>
</header> 


<main class="main">
  <div class="main__breadcrumbs container">
    <div class="breadcrumbs">
      <a class="breadcrumbs__item" href="./">Home</a>
      <a class="breadcrumbs__item" href="./">Company</a>
      <span class="breadcrumbs__item breadcrumbs__item_current">CBM Teams</span>
    </div>
  </div>

  <section class="p-layout container">
    <div class="p-layout__section">
      <div class="p-layout__side">
        <div class="t-block">
          <h1 class="t-block__title title">
            Expert teams dedicated to saving lives
          </h1>
          <div class="t-block__text t-block__text_large">
            <p>
              The deeply experienced team at the Center for Breakthrough
              Medicines (CBM) is our greatest asset – and yours too.
            </p>

            <p>
              Our people have led cell and gene therapy programs at innovators
              and CDMOs, including pioneers who are among the small universe of
              people to have taken advanced therapies to commercialization.
            </p>
          </div>
        </div>
      </div>
      <div class="p-layout__image p-layout__image_bgup-2 p-layout__image_plain">
        <img src="./images/stuff/content-image-9.png" alt="" />
      </div>
    </div>
  </section>

  <section class="p-team container">
    <div class="p-team__top">
      <h2 class="p-team__title title title_subtitle">Management Team</h2>
    </div>
    <div class="p-team__items p-team__items_decored">
      <div class="p-team__item" data-modal="#">
        <div class="p-team__wrapper">
          <div class="p-team__image p-image">
            <img src="./images/stuff/people-1.png" alt="" />
          </div>
          <div class="p-team__name">
            <span>Audrey Greenberg</span>
            <span>Co-Founder, Executive Managing Director</span>
          </div>
        </div>
        <div class="p-team__text">
          Audrey Greenberg is the Co-founder, Executive Managing Director and
          Board Member of The Center for Breakthrough Medicines. AudreyвЂ™s area
          of expertise is in capital structure, business formation,
          acquisitions, strategic planning and tactical execution. AudreyвЂ™s
          deep industry experience includes biotechnology, real estate, pharma
          services, and financial services. Prior to starting The Center for
          Breakthrough Medicines, Audrey spent several years in investment
          banking, public accounting and private equity having worked at some of
          the largest asset managers in the world with AUM exceeding $100
          billion. Audrey is passionate about supporting her community and
          serves on several non-profit boards including the King of Prussia
          Business District and is currently an Emissary for Select Greater
          Philadelphia, a division of the Philadelphia Chamber of Commerce
          responsible for attracting business to Greater Philadelphia. Audrey
          was recently selected by Philadelphia Magazine as one of the top
          trailblazers in Biotech and was featured on the cover of Main Line
          TodayвЂ™s Power Women edition. Audrey has an MBA from The Wharton
          School and is a registered CPA in Illinois.
        </div>
      </div>
      <div class="p-team__item" data-modal="#">
        <div class="p-team__wrapper">
          <div class="p-team__image p-image">
            <img src="./images/stuff/people-2.png" alt="" />
          </div>
          <div class="p-team__name">
            <span>Joerg Ahlgrimm</span>
            <span>President & CEO</span>
          </div>
        </div>
        <div class="p-team__text">
          <p>
            Joerg Ahlgrimm is the President and Chief Executive Officer at The
            Center for Breakthrough Medicines. He is an Operations and Supply
            Chain Management Executive who has served in multi-billion dollar
            companies operating in biotech, vaccines, pharmaceutical and medical
            device markets. He is the former Head of Global Operations Pharma
            and Biotech at Lonza AG where he was responsible for 37 sites on
            four continents. Prior to Lonza, he headed the Manufacturing network
            of Baxter Bioscience/Baxalta with 17 plants, a significant CMO
            network and the largest plasma collection division of the company.
            His prior roles also included responsibility for Supply Chain for
            Baxter Bioscience.
          </p>
          <p>
            Joerg has a passion for saving lives which is his main motivator to
            work in healthcare. He enjoys leading teams to achieve unprecedented
            performance levels and to create a work environment where people
            bring their best. In 2014 he was awarded вЂњEmerging Pharma Leader.
          </p>
        </div>
      </div>
      <div class="p-team__item" data-modal="#">
        <div class="p-team__wrapper">
          <div class="p-team__image p-image">
            <img src="./images/stuff/people-3.png" alt="" />
          </div>
          <div class="p-team__name">
            <span>Alan Moore</span>
            <span>Chief Strategy Officer</span>
          </div>
        </div>
        <div class="p-team__text">
          <p>
            "Alan Moore is Chief Strategy Officer at The Center for Breakthrough
            Medicines. Alan oversees new client development and on-boarding,
            building strategic partnerships and collaborations. He has 40 years
            of experience in the Life Sciences contract services field and most
            recently served as Vice President and Head of Strategic Alliances at
            WuXi Advanced Therapies. He was responsible for developing and
            maintaining strategic manufacturing relationships for autologous,
            allogeneic and gene-mediated cell and gene therapies, and strategic
            partnering in biologics services, Prior to that he served as
            Commercial Chief with primary responsibility for alignment of
            strategic partnering, business development efforts, and external
            collaborations. He oversaw the capital investment and capacity
            expansion for advanced therapies manufacturing at the Philadelphia
            Navy Yard campus. Prior to WuXi, he served as Executive VP and Chief
            Business Officer at Althea Technologies following his service at
            Genzyme where he held a Senior Regulatory Coordinator and VP of
            Biopharm Development Services position. His business unit
            manufactured early personalized therapies in conjunction with the
            NCI for phase III clinical trials of B cell lymphoma and multiple
            myeloma. Alan spent 16 years at Bioreliance moving from the lab to
            quality, and eventual management of the Biotech Services Division,
            and later serving as Director Business Development.
          </p>
        </div>
      </div>
      <div class="p-team__item" data-modal="#">
        <div class="p-team__wrapper">
          <div class="p-team__image p-image">
            <img src="./images/stuff/people-4.png" alt="" />
          </div>
          <div class="p-team__name">
            <span>Matthew Farabaugh</span>
            <span>Chief Financial Officer</span>
          </div>
        </div>
        <div class="p-team__text">
          <p>
            Matthew Farabaugh is the Chief Financial Officer of The Center for
            Breakthrough Medicines. Matt has over 19 years of finance and
            business experience in clinical and basic research of immunology,
            oncology, cell and gene therapy, and infectious diseases. He was
            previously Finance Manager at WuXi Advanced Therapies where he was
            responsible for revenue and contract management of $100MM in US
            revenue for research, manufacturing, and testing portfolio related
            to cell and gene therapy products. Prior to this Matthew served as a
            member of the UPENN-Novartis Global Program Team under Dr. Carl June
            and was responsible for a $50MM annual clinical development plan
            focused on FDA approval of cutting-edge CAR T cell therapy Kymriah
            in pediatric patients with relapsed acute lymphoblastic leukemia. He
            has a BS in Microbiology from Duquesne University, an MS in
            Molecular Biotechnology from the University of Pennsylvania and
            finance training from the Wharton School of Business.
          </p>
        </div>
      </div>
      <div class="p-team__item" data-modal="#">
        <div class="p-team__wrapper">
          <div class="p-team__image p-image">
            <img src="./images/stuff/people-5.png" alt="" />
          </div>
          <div class="p-team__name">
            <span>Peter Carbone</span>
            <span>Chief Operating Officer</span>
          </div>
        </div>
        <div class="p-team__text">
          <p>
            Peter Carbone is the Chief Operating Officer at Center for
            Breakthrough Medicines. He is the former Executive Vice President of
            Quality and Operations at Acorda Therapeutics and Head of Americas
            and Special Technologies for Novartis. Peter has over 30 years of
            Operations, Quality, and Technology leadership experience focused on
            building out or advancing global capabilities within small to large
            Pharmaceutical companies including Acorda, Novartis, Amgen, and
            Bayer. Peter is an accomplished Operations and Quality Executive who
            has served in multi-billion-dollar companies operating in biotech,
            pharmaceutical, and medical device markets. He focuses on the
            strategic buildout of agile, best in class operations, systems, and
            organizations.
          </p>
        </div>
      </div>
      <div class="p-team__item" data-modal="#">
        <div class="p-team__wrapper">
          <div class="p-team__image p-image">
            <img src="./images/stuff/people-6.png" alt="" />
          </div>
          <div class="p-team__name">
            <span>Dana Cipriano</span>
            <span>VP of Testing and Analytical Services</span>
          </div>
        </div>
        <div class="p-team__text">
          <p>
            Dana Cipriano is Vice President of Testing and Analytical Services
            The Center for Breakthrough Medicines. Dana has over a 20-year
            career in biotechnology and cell and gene therapy with leadership
            roles in Laboratory Operations and Project Management, with focus on
            designing processes and testing programs to drive sustainable growth
            and profitability. She was most recently Senior Director of Testing
            Operations and Strategic Projects for WuXi Advanced Therapies where
            she directed testing operations for cell and gene therapy and
            biologics testing, including characterization, release, safety and
            viral clearance testing for clinical and commercial products. She
            also helped create the overall testing business strategy, drove
            tactical implementation plans and monitored key milestones to drive
            delivery of strategic objectives. Dana developed a fully-integrated
            program for development of a new corporate strategy centered on
            driving scalability in cell and gene therapy testing services,
            including design and construction of a new cGMP testing facility.
            Dana has a Masters in Microbiology from Thomas Jefferson University,
            a BachelorвЂ™s in Biology from Rutgers University, an Executive
            Education Certification from The Wharton School, and a PMP (Project
            Management Professional) certification.
          </p>
        </div>
      </div>
      <div class="p-team__item" data-modal="#">
        <div class="p-team__wrapper">
          <div class="p-team__image p-image">
            <img src="./images/stuff/people-7.png" alt="" />
          </div>
          <div class="p-team__name">
            <span>Mike McCormick</span>
            <span>VP of Quality and Compliance</span>
          </div>
        </div>
        <div class="p-team__text">
          <p>
            Mike McCormick is the Vice President of Quality and Compliance at
            The Center for Breakthrough Medicines. He has over 20 years
            experience specializing in Quality Assurance, Quality Control,
            Operations and Regulatory Affairs, within the biotechnology, cell
            and gene therapy, and pharmaceutical industries with a proven track
            record of success in maximizing performance, scaling quality
            commercial operations and streamlining quality systems, while
            maintaining the highest levels of compliance with global regulations
            over multi-site operations. Prior to joining, Mike spent seven years
            as the V.P of Quality Assurance and Regulatory Affairs at WuXi
            Advanced Therapies and held similar leadership roles supporting the
            commercial manufacturing of API's.
          </p>
          <p>
            While leading the Quality and Regulatory Programs for Cell and Gene
            Therapy, Viral Vector, and Commercial Lot Release for Biological
            Products, Mike successfully represented Site Operations and Quality
            programs during inspections from global regulatory agencies
            resulting in successful outcomes: GMP Certificates (EMA and
            TGA,(3)), Marketing Authorization Approval (MAA) in Japan (PMDA),
            Korean FDA Inspections (KFDA, (2)) and successful outcomes of
            multiple FDA inspections (3).
          </p>
          <p>
            The GMP programs inspected supported the following manufacturing
            products: Viral Vector Products (11), Gene Mediated Cell Therapy
            Products (8), and Cell Therapy Products (12).
          </p>
          <p>
            Mike has his MBA with an emphasis in Biotechnology and Health
            Industry from Penn State University and attended the University of
            the Sciences in Philadelphia where his field of study was
            Pharmacology and Toxicology.
          </p>
        </div>
      </div>
      <div class="p-team__item" data-modal="#">
        <div class="p-team__wrapper">
          <div class="p-team__image p-image">
            <img src="./images/stuff/people-8.png" alt="" />
          </div>
          <div class="p-team__name">
            <span>Emily Moran</span>
            <span>VP of Vector Manufacturing</span>
          </div>
        </div>
        <div class="p-team__text">
          <p>
            Emily Moran is Vice President of Vector Manufacturing at Center for
            Breakthrough Medicines. She is an experienced leader in cell and
            gene therapy and biologics manufacturing with a focus on commercial
            readiness, industrialization, and manufacturing stabilization. She
            most recently served as Head of Viral Vector Manufacturing at Lonza
            in Houston Texas.While at Lonza, she facilitated the scale out and
            scale up of multiple clinical and commercial gene therapy programs
            as well as the expansion of the viral vector facility. Prior to
            Lonza, Emily worked in multiple areas of operations at Sanofi
            Pasteur. She is experienced in gene therapy and large scale
            biologics manufacturing, aseptic processing and filling, supply
            chain and demand planning, and quality auditing, all with a focus on
            operational excellence. Emily enjoys leading and developing large,
            high-performing teams and building patient and asset centricity. She
            has a B.S. in Biology from Ursinus College and an MBA in Project
            Management from New York Institute of Technology.
          </p>
        </div>
      </div>
      <div class="p-team__item" data-modal="#">
        <div class="p-team__wrapper">
          <div class="p-team__image p-image">
            <img src="./images/stuff/people-9.png" alt="" />
          </div>
          <div class="p-team__name">
            <span>Sybil Danby</span>
            <span>Senior VP of Business Development and Strategy</span>
          </div>
        </div>
        <div class="p-team__text">
          <p>
            Sybil Danby, Senior Vice President of Business Development and
            Strategy. She joined The Center for Breakthrough Medicines with 15
            years of industry experience across both technical and commercial
            roles. Most recently, Sybil was responsible for Business Development
            at Paragon Bioservices, which was acquired by Catalent Pharma
            Solutions in 2019 for $1.2 billion. In that role she interfaced with
            over 40 clients from top-tier gene therapy companies, negotiated
            large strategic contracts, and more than doubled the business every
            year for three years straight. Prior to joining Paragon, Sybil was
            part of the Single Use Technologies Business Unit at Pall,
            supporting upstream customers to adopt innovative single-use
            bioreactor technologies for the production of advanced therapies
            including AAV gene therapies, oncolytic viruses, and cell therapies.
            Sybil spent nine years at GSK, working in both the manufacturing and
            R&amp
          </p>
        </div>
      </div>
      <div class="p-team__item" data-modal="#">
        <div class="p-team__wrapper">
          <div class="p-team__image p-image">
            <img src="./images/stuff/people-10.png" alt="" />
          </div>
          <div class="p-team__name">
            <span>Oliver Mellet</span>
            <span>VP of Information Technology and Security</span>
          </div>
        </div>
        <div class="p-team__text">
          <p>
            Oliver Mellet is the Vice President of Information Technology and
            Security at The Center for Breakthrough Medicines. Oliver has broad
            experience in delivering IT and IT Security solutions in the pharma
            and healthcare sectors at Merck and Penn Medicine in the support of
            cancer research, clinical trials, drug safety, cGMP supply chain and
            manufacturing, and system security. He is known for delivering
            measurable results for complex problems in large-scale corporate
            landscapes. He holds a BS in Mechanical Engineering and a MasterвЂ™s
            degree in Management from the University of Pennsylvania (Wharton
            and SEAS)
          </p>
        </div>
      </div>
      <div class="p-team__item" data-modal="#">
        <div class="p-team__wrapper">
          <div class="p-team__image p-image">
            <img src="./images/stuff/people-11.png" alt="" />
          </div>
          <div class="p-team__name">
            <span>Eileen Brett</span>
            <span>VP Program Leadership</span>
          </div>
        </div>
        <div class="p-team__text">
          <p>
            Eileen Brett is the Vice President of Program Leadership at The
            Center for Breakthrough Medicines. Eileen has a 25+ year career in
            biotechnology including cell and gene therapy with Process
            Engineering and Program Leadership roles in Capital Projects, Supply
            Chain and R&amp
          </p>
        </div>
      </div>
      <div class="p-team__item" data-modal="#">
        <div class="p-team__wrapper">
          <div class="p-team__image p-image">
            <img src="./images/stuff/people-12.png" alt="" />
          </div>
          <div class="p-team__name">
            <span>Brian Tomkawicz</span>
            <span
              >Senior Director of Vector Engineering and Manufacturability</span
            >
          </div>
        </div>
        <div class="p-team__text">
          <p>
            Brian Tomkowicz is the Sr. Director of Vector Engineering and
            Manufacturability at The Center for Breakthrough Medicines, leading
            internal vector engineering efforts for LV, AAV, and Ad, as well as
            manufacturability assessment / platform development to support
            commercial manufacturing. Brian previously worked for close to a
            decade at Janssen Pharmaceuticals where he established JanssenвЂ™s
            internal gene therapy program and viral production capabilities (LV
            and AAV). He was a member of JanssenвЂ™s acquisition team that led
            to the purchase of 4 clinical-stage (Ph1/Ph2) ocular disease gene
            therapy programs. Brian completed two academic post-docs at the
            University of Pennsylvania focused on viral-induced chemokine and
            integrin receptor signaling. From there he took a position at a
            biotech start-up, Morphotek, where he rose to the level of Group
            Leader leading several early-stage clinical development programs for
            cancer antibody therapeutics. Brian has dozens of peer-reviewed
            publications along with multiple issued patents pertaining to novel
            inventions in antibody and gene therapy areas. He has a BS in
            Microbiology from The Pennsylvania State University and a PhD in
            Molecular Virology from Thomas Jefferson University.
          </p>
        </div>
      </div>
      <div class="p-team__item" data-modal="#">
        <div class="p-team__wrapper">
          <div class="p-team__image p-image">
            <img src="./images/stuff/people-13.png" alt="" />
          </div>
          <div class="p-team__name">
            <span>Kevin Arnaud</span>
            <span>Project Director</span>
          </div>
        </div>
        <div class="p-team__text">
          <p>
            Kevin Arnaud is a Project Director at The Center for Breakthrough
            Medicines. He is an experienced project leader with nearly 15 years
            in the pharmaceutical industry and most recently served as a Global
            Tech Transfer Leader for Sanofi Pasteur. In this role, Kevin worked
            to identify and select external contract manufacturing and testing
            partners around the globe and then implemented the technical and
            business processes between the two organizations. KevinвЂ™s
            additional experience in the biopharma industry includes
            manufacturing technology, project management, manufacturing
            excellence, continuous improvement, and operations management. He
            brings a strong project management and technical background as well
            as a solid understanding of supply chain, operational excellence,
            and strategic planning. He holds a Bachelor of Science in
            Kinesiology from Penn State University, a Master of Business
            Administration from the University of Scranton, and a PMP (Project
            Management Professional) certification.
          </p>
        </div>
      </div>
      <div class="p-team__item" data-modal="#">
        <div class="p-team__wrapper">
          <div class="p-team__image p-image">
            <img src="./images/stuff/people-14.png" alt="" />
          </div>
          <div class="p-team__name">
            <span>Aldo Romano</span>
            <span>VP Commercial Development</span>
          </div>
        </div>
        <div class="p-team__text">
          <p>
            Aldo Romano is the Vice President of Commercial Development at The
            Center for Breakthrough Medicines. He has over 20 years of
            bioprocessing and cell and gene therapy experience with specific
            expertise in capital equipment and disposable process technologies.
            Aldo was previously Business Development Manager at GE Healthcare
            Life Sciences where he was responsible for growing their Enterprise
            Solutions business. Prior to this Aldo served at Advanced Scientific
            (now part of Thermo-Fisher) as a Healthcare Sales Manager in their
            OEM medical technology contract manufacturing unit. He began his
            career at Pall Corporation where he worked as a Director of Sales
            focused on the growth and adoption of single use technologies into
            the Biotech market. Aldo earned his BachelorвЂ™s degree in Biology
            from Binghamton University.
          </p>
        </div>
      </div>
      <div class="p-team__item" data-modal="#">
        <div class="p-team__wrapper">
          <div class="p-team__image p-image">
            <img src="./images/stuff/people-15.png" alt="" />
          </div>
          <div class="p-team__name">
            <span>Amiel Gross, Esq.</span>
            <span
              >Vice President, General Counsel, Chief Compliance Officer</span
            >
          </div>
        </div>
        <div class="p-team__text">
          <p>
            Amiel Gross, Esq. is Head of Legal at Center for Breakthrough
            Medicines. Mr. Gross brings over 20 years of combined legal
            experience to CFBM. He previously served as in-house corporate
            counsel for US subsidiaries of a large global company, and outside
            counsel at the law firms Dentons US LLP and Orrick LLP in New York.
            Mr. Gross earned his JD degree from the University of Texas School
            of Law where he attended on an NCAA academic scholarship. As an
            undergraduate at Southwestern University, Mr. Gross was an NCAA
            All-American collegiate baseball player, graduating with high honors
            and Phi Beta Kappa.
          </p>
        </div>
      </div>
      <div class="p-team__item" data-modal="#">
        <div class="p-team__wrapper">
          <div class="p-team__image p-image">
            <img src="./images/stuff/people-16.png" alt="" />
          </div>
          <div class="p-team__name">
            <span>Avi Nandi</span>
            <span>Head of Process Development</span>
          </div>
        </div>
        <div class="p-team__text">
          <p>
            Avi Nandi is the Head of Process Development at The Center for
            Breakthrough Medicines. He has 15+ years of industry experience in
            Gene Therapy, Viral Vectors, and Vaccines with a MS in Biology and
            MBA (Oct вЂ21) and has contributed to the regulatory approval of
            ZOLGENSMA in US and 10+ Rest of World markets. Avi supported a
            pipeline of 15+ gene therapy products in development from
            preclinical to Phase III development and led development and
            implementation of 4 gene therapy manufacturing processes across 4
            GMP and 3 laboratory sites. He also has 10+ years experience in
            vaccine and viral vector development including, AAV, adenovirus,
            herpesvirus, alphavirus, lentivirus, and RNA, past experiences
            include:
          </p>
          <ul>
            <li>
              AveXis / Novartis Gene Therapies вЂ“ Global Head of Technical
              Development
            </li>
            <li>
              Seqirus / CSL вЂ“ Head of Virology and Cell Culture, Process and
              Product Development Lead
            </li>
            <li>
              Novartis Vaccines and Diagnostics вЂ“ Technical Development
              Scientist, R&amp
            </li>
            <li>Harvard Medical School вЂ“ Viral Pathogenesis Scientist</li>
          </ul>
        </div>
      </div>
    </div>
  </section>

  <section class="p-team container">
    <div class="p-team__top">
      <h2 class="p-team__title title title_subtitle">Board of Directors</h2>
    </div>
    <div class="p-team__items p-team__items_decored">
      <div class="p-team__item" data-modal="#">
        <div class="p-team__wrapper">
          <div class="p-team__image p-image">
            <img src="./images/stuff/people-17.png" alt="" />
          </div>
          <div class="p-team__name">
            <span>Brian O’Neill </span>
            <span>Executive Chairman</span>
          </div>
        </div>
        <div class="p-team__text">
          <p>
            Brian O'Neill is the Executive Chairman of the Board for The Center
            for Breakthrough Medicines and is the Founder, Chairman and CEO of
            MLP Ventures, a leading venture capital and real estate investment
            firm, and Recovery Centers of America. MLP Ventures creates
            companies that utilize real estate as an integral part of their
            business, as well as internet-based marketplaces. Under his
            leadership, MLP Ventures has developed millions of square feet of
            laboratory, office, industrial, retail and residential real estate
            throughout the Northeast. All of MLP companies and real estate
            recycle existing buildings, which often require environmental
            remediation. Mr. O'Neill has a track record of starting, scaling and
            operating healthcare organizations.
          </p>
        </div>
      </div>
      <div class="p-team__item" data-modal="#">
        <div class="p-team__wrapper">
          <div class="p-team__image p-image">
            <img src="./images/stuff/people-18.png" alt="" />
          </div>
          <div class="p-team__name">
            <span>Richard Heany</span>
            <span>Director</span>
          </div>
        </div>
        <div class="p-team__text">
          <p>
            Rich Heany is the President of MLP Ventures and has over 25 years of
            experience in real estate acquisitions, development, leasing and
            deal structuring. He has completed the acquisition and leasing of
            millions of square feet of real estate throughout the United States.
            Rich has a Degree in Civil Engineering from Drexel University and an
            MBA in Finance from LaSalle University.
          </p>
        </div>
      </div>
      <div class="p-team__item" data-modal="#">
        <div class="p-team__wrapper">
          <div class="p-team__image p-image">
            <img src="./images/stuff/people-19.png" alt="" />
          </div>
          <div class="p-team__name">
            <span>Eustace Mita</span>
            <span>Director</span>
          </div>
        </div>
        <div class="p-team__text">
          <p>
            Eustace Mita is board member for The Center for Breakthrough
            Medicines and Chairman and Chief Executive Officer of Icona Resorts,
            which owns and manages hotel properties in Avalon, Diamond Beach and
            Cape May, New Jersey. Mr. Mita is also Chairman of Mita Management,
            a company with interests in automotive and real estate, and is the
            Chief Executive Officer of Achristavest, LLC, a developer of
            waterfront properties in New Jersey, Nantucket, Maryland, Utah and
            Pennsylvania. Prior to forming Mita Management and Achristavest, &lt
          </p>
        </div>
      </div>
      <div class="p-team__item" data-modal="#">
        <div class="p-team__wrapper">
          <div class="p-team__image p-image">
            <img src="./images/stuff/people-default.png" alt="" />
          </div>
          <div class="p-team__name">
            <span>Aslam Malik, Ph.D.</span>
            <span>Director</span>
          </div>
        </div>
        <div class="p-team__text">
          <p>
            Aslam serves as the Chief Executive Officer of SK pharmteco, a
            top-tier global CDMO. In this role, he is responsible for driving
            the companyвЂ™s strategic direction and increasing the value of the
            company. Under AslamвЂ™s leadership, SK pharmteco has achieved
            exponential growth in both small molecules and cell and gene
            therapies.
          </p>
          <p>
            Prior to SK pharmteco, Aslam served as the President and CEO of
            AMPAC Fine Chemicals (AFC), now an SK pharmteco company. Since
            joining AFC in 1991, Aslam supported various technical and executive
            leadership positions in Business Development, Research &amp
          </p>
          <p>
            Aslam received his Ph.D. in Organic Chemistry and has over 35 years
            of experience in the pharmaceutical fine chemicals industry.
          </p>
        </div>
      </div>
      <div class="p-team__item" data-modal="#">
        <div class="p-team__wrapper">
          <div class="p-team__image p-image">
            <img src="./images/stuff/people-default.png" alt="" />
          </div>
          <div class="p-team__name">
            <span>Donghoon Lee</span>
            <span>Executive Chairman</span>
          </div>
        </div>
        <div class="p-team__text">
          <p>
            Mr. Lee is currently a head of Bio Investment Center at SK Inc, an
            investment holding company of SK group. He is leading SK groupвЂ™s
            bio investment globally by serving as a chairman of BOD at SK
            Biopharm and as a board member at SK Pharmteco. Formerly, he was a
            head of global business at Donga ST and CEO of Donga Socio Holdings.
            Prior to joining Donga, he practiced as a partner at Samjong KPMG
            Investment Advisory in Korea. He has MBA from The Ohio State
            University and BBA from Seoul National University.
          </p>
        </div>
      </div>
    </div>
  </section>

  <section class="p-team container">
    <div class="p-team__top">
      <h2 class="p-team__title title title_subtitle">Advisors</h2>
    </div>
    <div class="p-team__items p-team__items_decored">
      <div class="p-team__item" data-modal="#">
        <div class="p-team__wrapper">
          <div class="p-team__image p-image">
            <img src="./images/stuff/people-20.png" alt="" />
          </div>
          <div class="p-team__name">
            <span>Marco Chacon, PhD</span>
          </div>
        </div>
        <div class="p-team__text">
          Dr. Marco ChacГіn is the Non-executive Chairman of the Board for The
          Center for Breakthrough Medicines and the Founder and former Chairman
          of Paragon Bioservices, Inc., a CDMO that specialized in process
          development and GMP manufacturing of viral vectors for gene therapy.
          In April of 2019 Paragon Bioservices, Inc. entered into a definitive
          agreement of sale for $1.2 billion with Catalent. ChacГіn is the
          Founder and President of IRAZГљ Bio-Holdings LLC., a company dedicated
          to developing indications that promote survival, prevent disease and
          improve quality of life for the elderly. The company is also
          developing technology in the fields of immuno-oncology and gene
          therapy. Formerly, ChacГіn served as Assistant Vice President of
          Industry Alliances at the University of Maryland, Baltimore. His
          educational background includes a Bachelor of Science degree from
          Youngstown State University and a Ph.D. in Nutritional Sciences from
          the University of Maryland. He currently serves on the Board of
          Trustees of the University of Maryland Foundation and was appointed in
          2016 to the Life Sciences Advisory Board by Governor Lawrence J.
          Hogan, Jr. Additionally, Dr. ChacГіn is the founding chair of The
          Board of Visitors of the University of Maryland Graduate School.
        </div>
      </div>
      <div class="p-team__item" data-modal="#">
        <div class="p-team__wrapper">
          <div class="p-team__image p-image">
            <img src="./images/stuff/people-21.png" alt="" />
          </div>
          <div class="p-team__name">
            <span>Jack Stoddard</span>
          </div>
        </div>
        <div class="p-team__text">
          <p>
            Jack Stoddard is a board member for The Center for Breakthrough
            Medicines, Executive Chairman of Eden Health and Board Member for
            Carrot. Jack most recently served as COO of Haven, the healthcare
            collaboration from J.P. Morgan, Amazon and Berkshire Hathaway. Prior
            to Haven, he served as an executive general manager for digital
            health at Comcast and was part of the founding team at Accolade, a
            Comcast Ventures-backed start-up that helps workers manage their
            health benefits. He was also part of the executive team that created
            claims processing engine Optum, which was later acquired by United
            Health. He is a senior operating leader with over two decades of
            experience applying technology, data, science, people, and design
            thinking to improve the healthcare consumer experience, elevate
            clinical quality and lower the total cost of care. He has proven
            leadership experience in understanding the market, setting growth
            strategy, and scaling transformational healthcare companies,
            including: Haven, Accolade, Optum, Health Dialog, and The Advisory
            Board. Jack holds an MBA from Harvard Business School and earned his
            bachelorвЂ™s degree at Denison University with highest honors. He
            serves on the boards of directors of Carrot, backed by Khosla
            Ventures and Eden Health, backed by Greycroft. He has also served on
            the Board of Trustees of the Philadelphia Outward Bound School.
          </p>
        </div>
      </div>
      <div class="p-team__item" data-modal="#">
        <div class="p-team__wrapper">
          <div class="p-team__image p-image">
            <img src="./images/stuff/people-default.png" alt="" />
          </div>
          <div class="p-team__name">
            <span>Matthew McDevitt</span>
          </div>
        </div>
        <div class="p-team__text">
          <p>
            Matt McDevitt is a board member for The Center for Breakthrough
            Medicines. He also specializes in the leasing and sale of
            life-sciences real estate for tenants and landlords. Matthew founded
            and served as Executive Vice President of Real Estate for BioMed
            Realty Trust, Inc. where he played an instrumental role in all
            acquisitions and major lease transactions for the company. During
            his 10-year span, he maximized the shareholder value, growing its
            market capitalization from $475 million to $8 billion. Prior to
            BioMed, Matthew served as president of McDevitt Real Estate
            Services, Inc., a full-service real estate provider focusing on the
            life science industry. Before founding MRES, he spent 10 years as a
            commercial real estate broker in the Washington, D.C. Metropolitan
            area.
          </p>
        </div>
      </div>
      <div class="p-team__item" data-modal="#">
        <div class="p-team__wrapper">
          <div class="p-team__image p-image">
            <img src="./images/stuff/people-22.png" alt="" />
          </div>
          <div class="p-team__name">
            <span>Tony Khoury</span>
          </div>
        </div>
        <div class="p-team__text">
          <p>
            Tony Khoury is a board member for The Center for Breakthrough
            Medicines. He is an experienced industry leader in life sciences,
            specifically, biologics and advanced therapies. As Executive Vice
            President a at Project Farma, Tony has spearheaded the firmвЂ™s
            growth in the biologics and most recently next generation medicines.
            Tony has extensive experience with small and large molecules
            including biologics, biosimilars, and cell and gene therapies. He
            has worked with small and large life science organizations including
            startups, academic centers, financial institutions and CMOs/CROs. He
            has led global programs greater than $350+ million in the following
            disciplines: project management, turnkey facility builds,
            automation, validation, engineering and serialization track and
            trace. Recently, Tony has pioneered the industrialization of
            advanced therapies including two FDA-approved cell and gene
            therapies. Tony has led the creation of Project Farma's Advanced
            Therapy Manufacturing Playbook which has helped develop the largest
            cell and gene therapy manufacturing footprint in the world.
          </p>
        </div>
      </div>
    </div>
  </section>

  <div class="p-joining container">
    <div class="p-joining__text">
      Join the breakthrough. <br />
      Find your future at CBM.
    </div>
    <a class="p-joining__button button" href="./">Explore Careers ></a>
  </div>
</main>

<footer class="footer"> 
	<div class="container">
		<div class="footer__inner">
			<div class="footer__left">
				<a class="footer__logo" href="./"><img src="./images/logo-large.png" alt=""></a>
				<div class="footer__address">
					<span>411 Swedeland Rd</span>
					<span>King of Prussia, PA 19406</span>
				</div>
			</div>
			<!-- <nav class="footer__navi">
				<a class="footer__navi-link" href="./page.html">Company</a>
				<a class="footer__navi-link" href="./page2.html">Capabilities</a>
				<a class="footer__navi-link" href="./page3.html">Careers at CBM</a>
				<a class="footer__navi-link" href="./page4.html">Contact Us</a>
				<a class="footer__navi-link" href="./">News</a>
			</nav> -->
			<!-- <div class="footer__social social">
				<a class="social__item social__item_linkd" href="./">Linkedin</a>
				<a class="social__item social__item_twitr" href="./">Twitter</a>
				<a class="social__item social__item_instg" href="./">instagram</a>
			</div> -->
			<div class="footer__side">
				<h3 class="footer__side-title">Connect With Our Team</h3>
				<div class="footer__side-links">
					<a class="footer__side-contact" href="./">Contact us</a>
					<a class="footer__side-linkd" href="./"></a>
				</div>
			</div>
			<!-- <form class="footer__form form form_footer" action="./">
				<h3 class="form__title">Connect With Our Team</h3>
				<div class="form__field"><input type="text" name="name" placeholder="Name"></div>
				<div class="form__field"><input type="text" name="company" placeholder="Company"></div>
				<div class="form__field"><input type="text" name="email" placeholder="Email"></div>
				<button class="form__submit button button_white" type="submit">Connect</button>
			</form> -->
		</div>
		<div class="footer__copy"><strong>Center for Breakthrough Medicines</strong> | Copyright 2022</div>
	</div>
</footer> 
<script type="text/javascript" charset="utf-8" src="jquery.min.js"></script>
<script src="common.js"></script> 
</body> 
</html> 

